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To the Editor:
We were pleased to receive the response from Escobedo, et al to our recent manuscript 
describing giardiasis diagnosis and treatment patterns in the United States. They shared a 
summary of similar diagnosis and treatment patterns among giardiasis patients in Cuba, 
notably, that diagnoses are often delayed. They offer a framework for understanding and 
addressing these patterns based on surveys conducted among Cuban patients, caregivers and 
physicians. We wish to thank them for their insights, and highlight opportunities for US 
clinical and public health professionals to explore and address factors underlying delayed 
diagnoses and ineffective treatment in this country.
As in Cuba, giardiasis is the most common parasitic infection in the United States and is 
diagnosed by healthcare providers when symptomatic patients engage their services. 
Because giardiasis is nationally notifiable in the United States, the Centers for Disease 
Control and Prevention (CDC) uses passive laboratory surveillance to collect data on 
giardiasis cases (1) as well as surveillance for disease outbreaks associated with Giardia 
(2,3). These systems provide information on the incidence of giardiasis in the United States, 
and offer important feedback to public health practitioners who work to reduce the burden of 
this parasitic infection. However, they cannot provide granular insight into patterns of 
gastrointestinal illness care-seeking behavior, giardiasis diagnosis, and resultant treatment.
Giardiasis is difficult to diagnose for many reasons, as Escobedo et al remind us, and 
delayed or incorrect diagnoses have important implications for patients and for antimicrobial 
stewardship. This dilemma motivated our recent article, and we relied heavily on US studies 
that suggested diagnostic delays do occur, and that clinical suspicion among healthcare 
providers was low, as it appears to be in Cuba-based studies (4,5). Giardiasis studies 
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involving focus groups and knowledge-attitude-practice surveys in the United States are 
limited, however, and we appreciate Escobedo et al’s succinct summary of this work in 
Cuba, and the conclusion that many factors influence diagnostic and treatment patterns 
including the behavior of patients, caregivers and healthcare providers.
We suspect that the lessons learned from the work Escobedo et al describe will be broadly 
beneficial despite differences in population, socioeconomics and healthcare infrastructure 
among countries. We also believe that public health has a role to play in addressing the 
challenge of a common disease often mistaken for similar ones, with pressure to treat 
correctly in a short amount of time. This role involves characterizing giardiasis care and 
treatment patterns, and importantly, the subsequent application of these data. Application 
might include 1) designing additional studies such as clinician and patient focus groups to 
understand the motivating reasons behind patterns such as delayed diagnoses or age-specific 
care as we observed in our study (6), or 2) developing tailored communications products to 
assist those at risk of giardiasis and their caregivers, and clinicians who work with 
gastrointestinal illness. We look forward to reading and collaborating on additional studies 
like these in US populations.
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